Newsletter Signup | Join Community
Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and improve survival.
Selpercatinib is a precision cancer medicine that targets RET in some NSCLC patients.
Tepotinib is a novel precision cancer medicine capable of targeting NSCLC with MET 14 exon skipping alterations
Keytruda is the standard of care for PD-1 + NSCLC. Longer follow continues to confirm advantage over chemotherapy.
Opdivo® superior to Taxotere for treatment of recurrent NSCLC - Improves survival five fold!
Research suggests Metformin a widely used diabetic drug combined with a TKI may improve survival of EGFR mutated NSCLC.
The c-Met inhibitor Capmatinib is a promising novel precision cancer medicine for the treatment of EGFR + NSCLC.
Tarceva™ Improves Survival in Non-Small Cell Lung Cancer
I have small cell lung cancer; radiation to prevent spread to the brain has been recommended but…
HER 2 + Lung Cancer Treatment? https://coloradocancerblogs…
Dana Farber and MDACC discover why anti-PD 1 immunotherapy doesnt work in some patients and work to…
High incidence of ROS 1 false negative tests reported by U Colorado researchers. http://www…